Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study
- PMID: 16616355
- DOI: 10.1016/j.cgh.2006.01.002
Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study
Abstract
Background & aims: Cancer risks for mismatch repair gene mutation carriers have been derived almost exclusively using families ascertained owing to their strong cancer family history. These may be overestimates, due to analytic problems, and not generalizable. We estimated average cancer risks for mutations identified in population-based early onset colorectal cancer cases (probands) unselected for family history.
Methods: Data were cancer histories and mutation status (carrier, non-carrier, or unknown) of 17 mismatch repair gene mutation carrier probands with colorectal cancer diagnosed before age 45 (8 hMLH1, 4 hMSH2, 4 hMSH6, 1 hPMS2) and their first- and second-degree relatives. We used modified segregation analysis theory, adjusting for the family being ascertained through the proband being an early onset mutation carrier.
Results: Eleven carrier probands (64%) were from families meeting the Amsterdam II criteria for hereditary nonpolyposis colorectal cancer. The cumulative risk for colorectal cancer (95% confidence interval) to age 70 was 45% (29%-62%) for men and 38% (19%-51%) for women. Corresponding risks were 67% (47%-84%) and 72% (48%-85%) for any hereditary nonpolyposis colorectal cancer-related cancer. Compared with the general population, colorectal cancer incidence for men was approximately 180-fold higher before age 50, but about the same after age 50. For women, incidence was approximately 100-fold higher before age 50 and 7-fold higher thereafter.
Conclusions: For carriers of the mutations in the mismatch repair genes that cause early onset colorectal cancer, colorectal cancer increases rapidly until age 50, and the incidence decreases to general population levels at older ages.
Similar articles
-
Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.J Clin Oncol. 2005 Sep 20;23(27):6524-32. doi: 10.1200/JCO.2005.04.671. Epub 2005 Aug 22. J Clin Oncol. 2005. PMID: 16116158
-
Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer.Hum Genet. 1999 Jul-Aug;105(1-2):79-85. doi: 10.1007/s004399900064. Hum Genet. 1999. PMID: 10480359
-
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.J Natl Cancer Inst. 2013 Feb 20;105(4):274-9. doi: 10.1093/jnci/djs525. Epub 2013 Feb 5. J Natl Cancer Inst. 2013. PMID: 23385444 Free PMC article.
-
Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review.Am J Epidemiol. 2002 Nov 15;156(10):885-902. doi: 10.1093/aje/kwf139. Am J Epidemiol. 2002. PMID: 12419761 Review.
-
Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database.Dis Markers. 2004;20(4-5):269-76. doi: 10.1155/2004/305058. Dis Markers. 2004. PMID: 15528792 Free PMC article. Review.
Cited by
-
Cumulative risks of colorectal cancer in Han Chinese patients with Lynch syndrome in Taiwan.Sci Rep. 2021 Apr 26;11(1):8899. doi: 10.1038/s41598-021-88289-2. Sci Rep. 2021. PMID: 33903664 Free PMC article. Clinical Trial.
-
The Inherited and Familial Component of Early-Onset Colorectal Cancer.Cells. 2021 Mar 23;10(3):710. doi: 10.3390/cells10030710. Cells. 2021. PMID: 33806975 Free PMC article. Review.
-
Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers.Ann Surg Oncol. 2013 Jun;20(6):1829-36. doi: 10.1245/s10434-012-2858-5. Epub 2013 Jan 29. Ann Surg Oncol. 2013. PMID: 23358792 Free PMC article.
-
ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.Am J Gastroenterol. 2015 Feb;110(2):223-62; quiz 263. doi: 10.1038/ajg.2014.435. Epub 2015 Feb 3. Am J Gastroenterol. 2015. PMID: 25645574 Free PMC article. Review.
-
Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer.Onco Targets Ther. 2018 Oct 23;11:7295-7300. doi: 10.2147/OTT.S167645. eCollection 2018. Onco Targets Ther. 2018. PMID: 30425520 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical